

Manage small, low-exudating wounds with disposable NPWT.

3M ÷ KCI[™]



Silent Cartridge Technology

All the power of negative pressure wound therapy without the help of a battery.



Patient-Friendly Features

- Small, lightweight design can be hidden under clothes
- No batteries to interfere with daily living
- Visual indicator displays when cartridge is full or discharged

Innovative Design

- Proprietary spring mechanism generates consistent, even levels of pressure²
- BIOLOCK[™] Technology gels exudate for exudate containment
- -125mmHg pressure setting





SNAP[™] Therapy System

Combines the simplicity of advanced wound dressings with the proven benefits¹ of negative pressure wound therapy in a discreet design.

Clinical Evidence

Armstrong¹

In a multicenter RCT, 132 patients with lower extremity diabetic and venous wounds were enrolled in the study. 118 patients were treated either with SNAP[™] System (n=59) or V.A.C.[®] Therapy (n=56), with 115 patients completing the study.

- Patients were treated for up to 16 weeks or complete wound closure.
- Primary end point analysis of wound size reduction found that SNAP[™] System treated subjects demonstrated non-inferiority to V.A.C.[®] Therapy subjects at 4, 8, 12 and 16 weeks (*p*=0.0030, 0.0130, 0.0051 and 0.0044, respectively).
- The study indicated that the effect of the SNAP[™] System was not significantly different than that of the V.A.C.[®] Therapy System in promoting complete wound closure in the population studied (p=0.9620).
- SNAP[™] System patients reported less interruption of activities on daily living compared to V.A.C.[®] Therapy patients. However, pain associated with treatment was not significantly different between treatment groups.
- Other benefits noted by the authors were shorter time to dressing application and ease of use.
- However, despite randomization, the initial wound size was significantly greater in the V.A.C.[®] Therapy patients than in the SNAP[™] System patients (mean of 9.95cm² vs 5.37cm²; *p*=0.0093)

Marston³

In a multicenter RCT, 40 patients with venous leg ulcers were treated either with SNAP[™] System (n=19) or V.A.C.[®] Therapy (n=21)

- Patients were evaluated for 16 weeks or complete wound closure.
- Primary end point analysis of wound size reduction found that SNAP[™] System treated subjects had significantly greater wound size reduction than in V.A.C.[®] Therapy subjects at 4, 8, 12 and 16 weeks (*p*-value=0.0039, 0.0086, 0.0002, and 0.0005, respectively).
- 53% of SNAP[™] System patients achieved 50% wound closure at 30 days compared to 24% of V.A.C.[®] Therapy patients.
- However, despite randomization, the initial wound size was significantly greater in the V.A.C.[®] Therapy patients than in the SNAP[™] System patients (mean of 11.6cm² vs 4.49cm²).

SNAP[™] Advanced Dressing Kits

Proprietary hydrocolloid dressing offers periwound protection and easy removal. Additional accessories are designed to simplify dressing applications.


SNAP[™] Advanced Hydrocolloid Dressings

- Absorptive hydrocolloid properties help to maintain seal in the presence of exudate or sweat to help reduce periwound maceration
- Disposable components with off-the-shelf convenience
- Fully-integrated microport enables flexibility and a tight bending radius for wounds located in difficult areas
- Cut-to-length tubing and integrated one-way flow for improved safety
- Available in two sizes: 10cm x 10cm and 15cm x 15cm

Specialty Bridge Dressing


- Completely flat, comfortable dressing surface to help minimize further pressure damage
- Integrated bridge and port for one-step application
- Soft pad cushioning under bridge for improved patient comfort

Usage Locations:



Diabetic Foot Ulcer

Acute Wounds



Interface Layers

- Available with a BLUE foam interface
- Facilitates even levels of negative pressure²



- Fast and easy sealing on uneven skin surfaces and challenging body contours
- Reduces accessories needed to seal and protect the wound from moisture
- Increased adhesion of the SNAP[™] Dressing on dry and uneven skin

SNAP[™] Therapy Strap

• Soft strap enables device to be conveniently and discreetly worn under clothes







Ordering Information

NAP [™] Therapy Cartridge		
Catalog Number	Pressure	Capacity
SNPA125US	-125mmHg	60ml
SNPA125US/10	-125mmHg	60ml
NAP [™] Advanced Dressing	g Kit	
Catalog Number	Size	Interface
SKTF10X10	10cm x 10cm	Foam
SKTF10X10/10	10cm x 10cm	Foam
SKTF15X15	15cm x 15cm	Foam
SKTF15X15/10	15cm x 15cm	Foam
NAP [™] Bridge Dressing Kit	t	
Catalog Number	Size	Interface
BKTF14X11	14cm x 11cm	Foam
BKTF14X11/10	14cm x 11cm	Foam
BKTF14X11S	14cm x 11cm with SecurRing [™] Hydrocolloid	Foam
BKTF14X11S/10	14cm x 11cm with SecurRing [™] Hydrocolloid	Foam
NAP [™] SecurRing [™] Hydrod	colloid	
Catalog Number		Size
SRNG10)	2" diameter
NAP [™] Therapy Strap		
Catalog Number		Size
STPAS		Small 18"
STPAM	l .	Medium 21"
STPAL		Large 24"

To order product or for more information, contact your local representative.

References

1. Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. Wound Rep Reg 2012; 20(3):332-341.

2. Fong KD, Hu D, Eichstadt S et al. The SNaP system: biomechanical and animal model testing of a novel ultraportable negative-pressure wound therapy system. Plastic and Reconstructive Surgery. 2010 May;125(5):1362-71.

3. Marston WA, Armstrong DG, Reyzelman AM, Kirsner RS. A Multicenter Randomized Controlled Trial Comparing Treatment of Venous Leg Ulcers Using Mechanically Versus Electrically Powered Negative Pressure Wound Therapy. Advances in Wound Care. 2015;4(2):75-82. doi:10.1089/wound.2014.0575.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.



©Copyright 2020 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. LIT#29-A-263 • PRA-PM-US-00289 (04/20)